Enfermedad pulmonar intersticial asociada a esclerosis sistémica (EPI-ES)

 

Effects of nintedanib in patients with SSc-ILD and preserved and highly impaired lung function

Wuyts WA et al.
 

Acceder

FVC decline in patients with SSc-ILD by use of anti-acid therapy

Kreuter M et al.

 

Acceder

¿Te ha resultado útil esta información?